/NNVC
NNVC Stock - NanoViricides, Inc.
Healthcare|BiotechnologyAMEX
$1.24+2.48%
+$0.03 (+2.48%) • Dec 19
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.18
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.74
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.36
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NNVC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.23 – $1.25
TARGET (TP)$1.43
STOP LOSS$1.14
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.16
52W High$2.23
52W Low$0.94
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-9,591,645 | $-8,516,111 | $-8,943,468 | $-8,113,599 | $-8,744,106 |
| Net Income | $-9,466,966 | $-8,294,146 | $-8,588,573 | $-8,106,863 | $-8,822,189 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.63 | $-0.70 | $-0.74 | $-0.70 | $-0.81 |
Company Overview
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
No price targets available
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 16th 2025 | Alliance Global Partners | Initiation | Buy | - |
Earnings History & Surprises
NNVCBeat Rate
71%
Last 17 quarters
Avg Surprise
+6.7%
EPS vs Estimate
Beats / Misses
12/3
2 met exactly
Latest EPS
$-0.10
Q4 2025
EPS Surprise History
Q1 24
+5.3%
$-0.18vs$-0.19
Q2 24
+15.8%
$-0.16vs$-0.19
Q3 24
+5.0%
$-0.19vs$-0.20
Q4 24
-35.3%
$-0.23vs$-0.17
Q1 25
+22.2%
$-0.14vs$-0.18
Q2 25
+26.3%
$-0.14vs$-0.19
Q3 25
+35.0%
$-0.13vs$-0.20
Q4 25
+44.4%
$-0.10vs$-0.18
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Feb 13, 2026 | $-0.14 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.18 | $-0.10 | +44.4% | ✓ BEAT |
Q3 2025 | Sep 29, 2025 | $-0.20 | $-0.13 | +35.0% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.19 | $-0.14 | +26.3% | ✓ BEAT |
Q1 2025 | Feb 14, 2025 | $-0.18 | $-0.14 | +22.2% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.17 | $-0.23 | -35.3% | ✗ MISS |
Q3 2024 | Sep 27, 2024 | $-0.20 | $-0.19 | +5.0% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.19 | $-0.16 | +15.8% | ✓ BEAT |
Q1 2024 | Feb 14, 2024 | $-0.19 | $-0.18 | +5.3% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.17 | $-0.17 | 0.0% | = MET |
Q4 2023 | Oct 13, 2023 | $-0.17 | $-0.31 | -82.4% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.17 | $-0.15 | +11.8% | ✓ BEAT |
Q1 2023 | Feb 14, 2023 | $-0.16 | $-0.15 | +6.3% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q4 2022 | Oct 13, 2022 | $-0.23 | $-0.15 | +34.8% | ✓ BEAT |
Q2 2022 | May 17, 2022 | $-0.16 | $-0.16 | 0.0% | = MET |
Q1 2022 | Feb 14, 2022 | $-0.22 | $-0.17 | +22.7% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.20 | $-0.23 | -15.0% | ✗ MISS |
Q4 2021 | Oct 12, 2021 | — | $-0.18 | — | — |
Latest News
NanoViricides Signs Master Services Agreement With Only Orphans Cote To Advance Orphan Drug Strategy For NV-387
📈 PositiveBenzinga•Dec 1, 2025, 01:35 PM
NanoViricides To Present Data On NV-387 At Pharma Partnering Summit 2025
➖ NeutralBenzinga•Nov 14, 2025, 01:35 PM
NanoViricides Prices 3,571,429 Share Securities Purchase Agreement At $1.68/Share For Gross Proceeds $6M
➖ NeutralBenzinga•Nov 11, 2025, 01:34 PM
NanoViricides Receives DRC Approval To Start Phase II Trial Of NV-387 For MPox Treatment
📈 PositiveBenzinga•Nov 10, 2025, 01:35 PM
NanoViricides Announces CEO Dr. Anil Diwan Shares That Company's Lead Drug, NV-387, Demonstrated Potent Activity Against The Measles Virus In Cell Cultures And A Humanized Animal Model, Protecting Lung Tissue And Significantly Extending Survival—from 7.4 Days In Untreated Animals To 17 Days In Treated Ones
📈 PositiveBenzinga•Oct 29, 2025, 12:52 PM
NanoViricides Says Clinical Lead Drug NV-387 Shows Strong Activity Against Measles Virus In Cell Culture Studies As Well As In Humanized Animal Model
📈 PositiveBenzinga•Oct 22, 2025, 12:47 PM
NanoViricides Says Clinical Lead Drug NV-387 Shows Strong Activity Against Measles Virus In Humanized Animal Model; Says NV-387 Can Now Be Made Available For Emergency Use Application In Measles Patients
📈 PositiveBenzinga•Oct 20, 2025, 12:47 PM
NanoViricides Reports That An Analyst Research Report Was Published On The Company That Explains Its Dual-Track Clinical Trials For NV-387 Targeting MPox And Respiratory Viruses
➖ NeutralBenzinga•Oct 15, 2025, 12:47 PM
Nanoviricides Q4 EPS $(0.13) Up From $(0.19) YoY
📈 PositiveBenzinga•Sep 29, 2025, 09:55 PM
Frequently Asked Questions about NNVC
What is NNVC's current stock price?
NanoViricides, Inc. (NNVC) is currently trading at $1.24 per share. The stock has moved +2.48% today.
What is the analyst price target for NNVC?
No analyst price targets are currently available for this stock.
What sector is NanoViricides, Inc. in?
NanoViricides, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is NNVC's market cap?
NanoViricides, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does NNVC pay dividends?
No, NanoViricides, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
EVAX
Evaxion Biotech A/S
$4.70
Mkt Cap: $0.0B
GBIO
Generation Bio Co.
$5.54
Mkt Cap: $0.0B
IGC
IGC Pharma, Inc.
$0.30
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
MAIA
MAIA Biotechnology, Inc.
$1.22
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
SABS
SAB Biotherapeutics, Inc.
$3.99
Mkt Cap: $0.0B
TENX
Tenax Therapeutics, Inc.
$13.10
Mkt Cap: $0.1B
VRCA
Verrica Pharmaceuticals Inc.
$7.82
Mkt Cap: $0.1B
Explore stocks similar to NNVC for comparison